Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17879718 | 0.84 | JAK2 (0.37) | JAK2BTK | |
| SCHEMBL19657256 | 0.81 | — | — | |
| SCHEMBL20384529 | 0.79 | JAK2 (0.34) | JAK2BTK | |
| SCHEMBL23403836 | 0.78 | JAK2 (0.34) | JAK2BTK | |
| SCHEMBL24836998 | 0.76 | JAK2 (0.31) | JAK2BTK | |
| SCHEMBL19657265 | 0.73 | — | — | |
| SCHEMBL29613202 | 0.73 | BRD4 (0.46) | JAK2BTK | |
| SCHEMBL16649616 | 0.73 | BRD4 (0.46) | JAK2BTK | |
| SCHEMBL26195908 | 0.72 | — | — | |
| SCHEMBL21652828 | 0.72 | BUB1 (0.38) | JAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204500-A1 | COMPOUNDS COMPRISING N-METHYL-2-PYRIDONE, AND PHARMACEUTICALLY ACCEPTABLE SALTS | UNIVERSITY OF DUNDEE (GB) | 2022-06-30 | — | — | US | disclosed |
| WO-2022090699-A1 | PYRIDONE-CONTAINING COMPOUNDS AS BROMODOMAIN PROTEIN INHIBITORS | In4Derm Limited (GB) | 2022-05-05 | — | — | WO | disclosed |
| US-20210147419-A1 | BRD4 inhibitor as well as a preparative method and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2021-05-20 | — | — | US | disclosed |
| WO-2020216779-A1 | COMPOUNDS COMPRISING N-METHYL-2-PYRIDONE, AND PHARMACEUTICALLY ACCEPTABLE SALTS | UNIVERSITY OF DUNDEE (GB) | 2020-10-29 | — | — | WO | disclosed |
| US-20170342067-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147419-A1 | BRD4 inhibitor as well as a preparative method and use thereof | BICRA, BRD4, BRDT | JAK2 422/4885BTK 1612/4885 |
| US-20220204500-A1 | COMPOUNDS COMPRISING N-METHYL-2-PYRIDONE, AND PHARMACEUTICALLY ACCEPTABLE SALTS | TPMT, IL5, P2RY6 | JAK2 106/4885BTK 1208/4885 |
| US-20170342067-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRPF3 | JAK2 52/4885BTK 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.